Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the New York Eastern District Court on behalf of all persons or entities who acquired Misonix, Inc. (NASDAQ:MSON) securities between November 5, 2015 and September 14, 2016 (the "Class Period"). Misonix, Inc. is an international surgical device company that designs, manufactures, and markets innovative therapeutic ultrasonic products for spine surgery, neurosurgery, wound debridement, skull based surgery, laparoscopic surgery, and other surgical applications. According to the lawsuit, throughout the Class Period Misonix made false and/or misleading statements and/or failed to disclose that: (1) deficiencies existed in Misonix's internal controls over financial reporting; and (2) as a result, Defendants' statements about Misonix's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. On September 14, 2016, Misonix revealed that it will delay its Annual Report filing on Form 10-K for the fiscal year ended June 30, 2016 due to the pending investigation by Misonix's Audit Committee in connection to its defects in internal control over financial reporting at June 30, 2016. Following this news, Misonix shares fell sharply during trading on September 15, 2016. If you acquired Misonix securities during the Class Period or continue to hold shares purchased prior to the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact J. Brandon Walker, Esq. by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.